Cynata Therapeutics (CYP) reported positive safety and efficacy data from a day 28 analysis of patients in Cohort B of its Phase 1 clinical trial of CYP-001, the Company’s lead Cymerus mesenchymal stem cell product candidate, in steroid-resistant acute graft-versus-host disease (GvHD). These findings, together with the excellent data from Cohort A, support the advancement of CYP-001 into a Phase 2 trial in GvHD
http://crweworld.com/article/news-p...-cohort-b-of-phase-1-trial-of-cyp-001-in-gvhd
Ann: Positive 28-day Clinical Trial Data in Cohort B, page-45
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
-0.025(8.20%) |
Mkt cap ! $50.29M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 28.0¢ | $17.16K | 60.37K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 900 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 1400 | 1 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| CYP (ASX) Chart |